Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + trametinib to enable complete resection in BRAF-mutated unresectable stage III/IV melanoma
2013-002616-28Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Rate of R0 resection. Started Sep 2013; status: active.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2013-002616-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002616-28.